Novel Epigenetic Biomarker for Prematurity Related Neurodevelopmental Disorders in Childhood

Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (Other)
Overall Status
Recruiting
CT.gov ID
NCT04617587
Collaborator
Ministero della Salute, Italy (Other), Istituto Nazionale di Genetica Molecolare, Milan Italy (Other), IRCCS Humanitas Milan Italy (Other)
104
1
1
40.9
2.5

Study Details

Study Description

Brief Summary

Preterms are early exposed to a stressful environment (i.e. excessive sensory stimulation and paucity of parental contact) with subsequent detrimental effects on brain maturation and neurodevelopmental outcomes. In contrast, early interventions seem to reduce stress exposure and promote neurodevelopment. The brain functional plasticity in response to environmental experiences can be partly attributed to changes in DNA methylation. In this context, LINE-1 (L1) promoter (18% of human genome) methylation/demethylation has been associated with L1 somatic mobilization in the brain genomes, contributing to experience-driven brain plasticity; this mechanism being deregulated in important neurological disease. This study aims at identifying and characterizing the role of L1 DNA repeats as a novel biomarker to predict long-term neurodevelopmental outcome in preterm infants. In addition, the study's secondary goal will be to define a preventive approach, based on early intervention strategies, for improving long-term neurodevelopmental outcomes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Early Intervention
N/A

Detailed Description

Around 25-50% of very preterm infants suffer from neurodevelopmental delays (motor, cognitive and behavioral problems), which are most likely related to brain micro-structural defects and impaired neuronal maturation and connectivity. These alterations in brain maturation occurring during the neonatal period may be implicated in long-term neurobehavioral disorders later experienced by preterm babies.

There is increasing evidence that also stressful events (excessive sensory stimulation, paucity of parental contact and painful procedures) experienced in the Neonatal Intensive Care Unit (NICU) by preterm neonates can affect neurodevelopment through epigenetic mechanisms.

The brain is a genomic mosaic, owing to somatic mutations that arise throughout development. It is already established that mobile genetic elements, including LINE-1 (L1), are one source of somatic mosaicism, inducing copy number variations in neural genome. Environmental experiences can drive brain plasticity at a molecular level, with changes in DNA methylation. In particular, L1 promoter methylation/demethylation is already associated with L1 mobilization in the brain genomes and its deregulation is linked with important neurological diseases. A preliminary study has shown the correlation between L1 promoter methylation levels and preterm birth. In addition, maternal care during early life has been reported to drive variability in L1 mobilization and methylation of the neural hippocampal genome in mice models.

Several studies have reported how individualized developmental care in the NICU can ameliorate preterm infants' medical outcome and subsequent neurodevelopment. More recently, early intervention (EI) strategies based on parental training and multisensory stimulation, such as infant massage and visual stimulation, have been demonstrated to enhance child's neurodevelopment. These programs have the greatest potential to reduce environmental stress in preterms, promoting brain plasticity, optimizing dyadic interaction and ameliorating neurodevelopmental outcomes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
104 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Structural Variations of the Neural Genome as Prognostic Biomarkers for Prematurity Related Neurodevelopmental Disorders in Childhood
Actual Study Start Date :
Dec 3, 2020
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Early Intervention

All the enrolled preterm infants are assigned to receive the early neurodevelopmental intervention during the NICU stay.

Behavioral: Early Intervention
The early intervention (EI) is delivered during the NICU stay. It is a multisensory intervention which consists in three parts: parental training, massage therapy and visual interaction. The EI is first focused on parental training, according to PremieStart Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior through the identification of infant's behavioral states; adopt principles of graded stimulation; sustain infant's attention and respond to infant's cues; optimize interactions and avoid overwhelming infants through facilitation strategies. The program is held in eight main sessions and one additional post-discharge session. In addition, parents are trained and invited to daily promote preterm baby massage therapy and visual interaction (visual fixation/tracking and visual attention).

Outcome Measures

Primary Outcome Measures

  1. L1 Promoter Methylation Levels on Biological Materials [Up to 24 months corrected age]

    Epigenetic analysis is performed on biological materials: cord blood sample and buccal swab at birth, peripheral blood sample and buccal swab at NICU discharge/term equivalent age, buccal swab collected during the follow up assessment at 12 and 24 months of corrected age.

Secondary Outcome Measures

  1. Conventional and advanced brain Magnetic Resonance Imaging (MRI) [Term equivalent age, approximately 40 weeks postmenstrual age]

    Evaluation of brain development and maturation

  2. Neurological Examination [Term equivalent age, approximately 40 weeks postmenstrual age]

    Hammersmith Neonatal Neurological Examination (HNNE)

  3. General Movements Examination [Term equivalent age, approximately 40 weeks postmenstrual age]

    Prechtl's Qualitative Assessment of General Movements

  4. Visual Assessment [Term equivalent age, approximately 40 weeks postmenstrual age]

    Neonatal Visual Assessment Battery developed by Ricci et al. The assessment evaluates the following items: ocular spontaneous motility, ability to fix and follow a target, reaction to colour, visual acuity and visual attention at distance.

  5. Neurodevelopmental Outcome [Up to 24 months corrected age]

    Children development assessed using the Griffiths Mental Development Scales, performed at 12 and 24 months of corrected age. Mean score is 100. General score has a Standard deviation of 12 and sub scales have a Standard Deviation of 16. Higher scores indicate better outcomes.

  6. Behavioral Outcome [24 months corrected age]

    Children behavior assessed using the Child Behavior Checklist (CBCL). It is a parent report form to screen for emotional, behavioral and social problems. Lower scores indicate better outcomes. A T score above 75 is considered pathological while a T score between 65 and 74 is considered borderline.

Eligibility Criteria

Criteria

Ages Eligible for Study:
24 Weeks to 32 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Gestational age at birth between 24+0 and 32+6 weeks

  • Mothers age over 18 years

  • Good comprehension of the Italian language

  • Written informed consent signed by both parents

Exclusion Criteria:
  • Infants with major genetic disorders and malformations

  • Parents declined study participation

  • Single-parent family

  • Parents with obvious cognitive or psychiatric disorders and drug addiction

Contacts and Locations

Locations

Site City State Country Postal Code
1 NICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan Italy 20122

Sponsors and Collaborators

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
  • Ministero della Salute, Italy
  • Istituto Nazionale di Genetica Molecolare, Milan Italy
  • IRCCS Humanitas Milan Italy

Investigators

  • Principal Investigator: Monica Fumagalli, MD, PhD, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
  • Principal Investigator: Beatrice Bodega, PhD, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
ClinicalTrials.gov Identifier:
NCT04617587
Other Study ID Numbers:
  • GR-2018-12365280
First Posted:
Nov 5, 2020
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2022